Progenics Pharma (PGNX) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Progenics Pharmaceuticals Announces First Quarter 2015 Financial Results
May 6, 2015 8:01 AM EDTTARRYTOWN, N.Y., May 6, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced results of operations for the first quarter ended March 31, 2015.
"Our portfolio offers multiple opportunities to create value for our shareholders," stated Mark Baker, CEO of Progenics. "The recent positive CHMP opinion for subcutaneous RELISTOR, together with the upcoming U.S. NDA filing for the oral indication, highlight the multiple opportunities for growth in this important franchise. Our pivotal Phase 2b trial for Azedra is progressing as expected, and we remain on track to complete enrollment by year-end. For our... More
Progenics Pharmaceuticals Announces First Quarter 2015 Financial Results
May 6, 2015 8:00 AM EDTTARRYTOWN, N.Y., May 6, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced results of operations for the first quarter ended March 31, 2015.
"Our portfolio offers multiple opportunities to create value for our shareholders," stated Mark Baker, CEO of Progenics. "The recent positive CHMP opinion for subcutaneous RELISTOR, together with the upcoming U.S. NDA filing for the oral indication, highlight the multiple opportunities for growth in this important franchise. Our pivotal Phase 2b trial for Azedra is progressing as expected, and we remain on track to complete enrollment by year-end. For our... More
